InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total sales | $1.4M | $0 | $0 | $0 | $0 |
| Cost of goods | $181K | $0 | $0 | $0 | $0 |
| Gross profit | $1.2M | $0 | $0 | $0-100.0% | $75K |
| Research and development expense | $1.3M-45.2% | $2.3M-65.0% | $6.7M+31825.3% | $21K | $0 |
| Salary expense | $1.7M-2.0% | $1.7M+18.4% | $1.5M | — | — |
| Amortization expense | $1.0M+0.0% | $1.0M+0.0% | $1.0M | — | — |
| Professional services expense | $7.8M+164.1% | $3.0M-72.8% | $10.9M-65.1% | $31.1M | — |
| Stock based compensation expense | $1.2M+10.0% | $1.1M+131.4% | $478K | — | — |
| General and administrative expenses | $1.1M+21.4% | $946K-7.9% | $1.0M-66.4% | $3.1M-78.4% | $14.1M |
| Selling and marketing expense | $105K | $0 | — | $8K+185.5% | $3K |
| Total cost of operations | $14.2M+41.5% | $10.1M-53.2% | $21.5M-37.2% | $34.2M+142.2% | $14.1M |
| LOSS FROM OPERATIONS | -$13.0M-29.7% | -$10.1M+53.2% | -$21.5M+37.2% | -$34.2M-143.5% | -$14.0M |
| Interest expense | -$97K+60.7% | -$246K-128.6% | -$108K+50.7% | -$218K-16.7% | -$187K |
| Interest income | $116K-50.4% | $235K | — | — | — |
| Amortization of debt discount | -$546K-152.4% | -$216K | — | — | — |
| Gain on forfeiture of customer deposit | $115K | $0 | — | — | — |
| Other income (expense), net | $7K+142.6% | -$16K+92.5% | -$220K-323.4% | $99K | — |
| Unrealized gain on marketable securities | $77K | $0 | — | — | — |
| Unrealized loss on investments | -$164K | $0 | — | — | — |
| Loss on write down of assets | $0+100.0% | -$37K | $0 | — | — |
| Gain (loss) on extinguishment of debt | $159K+179.5% | -$200K | — | — | — |
| Change in fair value of derivative liabilities | $1.1M+421.4% | -$342K-160.2% | $568K | — | — |
| TOTAL OTHER INCOME (EXPENSE), net | $766K+193.1% | -$823K-466.4% | $225K+106.6% | -$3.4M-666.2% | $597K |
| LOSS BEFORE INCOME TAXES | -$12.3M-12.9% | -$10.9M+48.9% | -$21.3M+43.4% | -$37.6M-179.4% | -$13.4M |
| PROVISION FOR INCOME TAXES (BENEFIT) | $0 | $0 | $0 | $0 | $0 |
| NET LOSS | -$12.3M-12.9% | -$10.9M+48.9% | -$21.3M+43.4% | -$37.6M-179.4% | -$13.4M |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS | -$360K-82.9% | -$197K | $0 | — | — |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | -$11.9M-11.6% | -$10.7M | $0+100.0% | -$37.6M-179.4% | -$13.4M |
| Loss per share, basic | -$2.81+49.5% | -$5.56+66.4% | -$16.56 | — | — |
| Loss per share, fully diluted | -$2.81+49.5% | -$5.56+66.4% | -$16.56 | — | — |
| Weighted average number of common shares outstanding, basic | $4.2M+120.0% | $1.9M+49.8% | $1.3M | — | — |
| Weighted average number of common shares outstanding, diluted | $4.2M+120.0% | $1.9M+49.8% | $1.3M | — | — |
| Sale [Member] | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Z Squared Provides Additional Information on Previously Disclosed Pro Rata Distribution
Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market
Vanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds Build
Vanderbilt Report: Coeptis Therapeutics Shareholders Approve Transformational Merger: From Biopharma to Dual-Sector Platform